HK1192726A1 - 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5- - Google Patents

1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-

Info

Publication number
HK1192726A1
HK1192726A1 HK14105962.7A HK14105962A HK1192726A1 HK 1192726 A1 HK1192726 A1 HK 1192726A1 HK 14105962 A HK14105962 A HK 14105962A HK 1192726 A1 HK1192726 A1 HK 1192726A1
Authority
HK
Hong Kong
Prior art keywords
thiadiazol
treatment
neurodegenerative diseases
derivatives useful
ylpiperazine
Prior art date
Application number
HK14105962.7A
Other languages
English (en)
Chinese (zh)
Inventor
Gerard Griffioen
Matthias Nettekoven
Katrien Princen
Hasane Ratni
Walter Vifian
Original Assignee
Remynd Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remynd Nv filed Critical Remynd Nv
Publication of HK1192726A1 publication Critical patent/HK1192726A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
HK14105962.7A 2011-07-01 2014-06-23 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5- HK1192726A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11172324 2011-07-01
PCT/EP2012/062778 WO2013004642A1 (en) 2011-07-01 2012-06-29 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases

Publications (1)

Publication Number Publication Date
HK1192726A1 true HK1192726A1 (en) 2014-08-29

Family

ID=46545347

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14105962.7A HK1192726A1 (en) 2011-07-01 2014-06-23 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-

Country Status (10)

Country Link
US (1) US9023852B2 (xx)
EP (1) EP2726470B1 (xx)
JP (1) JP5972367B2 (xx)
CN (1) CN103619825B (xx)
AU (1) AU2012280420B2 (xx)
CA (1) CA2837247C (xx)
ES (1) ES2540956T3 (xx)
HK (1) HK1192726A1 (xx)
PL (1) PL2726470T3 (xx)
WO (1) WO2013004642A1 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103649062B (zh) * 2011-08-17 2015-10-07 瑞敏德股份有限公司 用于治疗tau病变如阿尔茨海默病的哌嗪噻唑衍生物
EP3119774A1 (en) * 2014-03-17 2017-01-25 reMynd NV Oxadiazole compounds
MX2018015170A (es) * 2016-06-23 2019-07-04 St Jude Childrens Res Hospital Moduladores de moleculas peque?as de pantotenato cinasas.
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
US11891378B2 (en) 2017-12-27 2024-02-06 St. Jude Children's Research Hospital, Inc. Small molecule modulators of pantothenate kinases
EP3731859A4 (en) 2017-12-27 2021-09-22 St. Jude Children's Research Hospital, Inc. METHODS OF TREATMENT FOR DISORDERS ASSOCIATED WITH CASTOR

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538152A (ja) * 1999-03-03 2002-11-12 ワイス セロトニン作動薬としての新規なジアゾール誘導体
JP2002543070A (ja) * 1999-04-26 2002-12-17 ニューロサーチ、アクティーゼルスカブ ヘテロアリールジアザシクロアルカン類、その製造方法及びその使用方法
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine
PE20070099A1 (es) * 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
GB0602335D0 (en) * 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
RU2008132333A (ru) * 2006-02-07 2010-03-20 Вайет (Us) Ингибиторы 11-бета hsd1

Also Published As

Publication number Publication date
WO2013004642A1 (en) 2013-01-10
JP2014518240A (ja) 2014-07-28
EP2726470B1 (en) 2015-04-29
US9023852B2 (en) 2015-05-05
ES2540956T3 (es) 2015-07-15
CN103619825B (zh) 2015-10-14
AU2012280420B2 (en) 2017-01-05
CN103619825A (zh) 2014-03-05
CA2837247C (en) 2020-03-31
CA2837247A1 (en) 2013-01-10
AU2012280420A1 (en) 2013-12-12
EP2726470A1 (en) 2014-05-07
PL2726470T3 (pl) 2015-09-30
US20140128404A1 (en) 2014-05-08
JP5972367B2 (ja) 2016-08-17

Similar Documents

Publication Publication Date Title
HRP20190491T1 (hr) Spojevi 1-arilkarbonil-4-oksi-piperidina korisni za liječenje neurodegenerativnih bolesti
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
AP2014007533A0 (en) Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
HRP20181950T1 (hr) Samidorfan (alks 33) u kombinaciji s buprenorfinom za liječenje depresivnih poremećaja
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
LT2838539T (lt) Estrogeniniai dariniai, skirti naudoti neurologinių sutrikimų gydymui
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
ZA201308176B (en) Therapeutic treatment
HK1208454A1 (zh) 治療細菌性疾病的嘧啶衍生物
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
EP2736439A4 (en) CLASS 1 LASER TREATMENT SYSTEM